Investors and partners
oncgnostics develops – based on proprietary epigenetic biomarkers – highly reliable in vitro
diagnostic tests for screening, therapeutic decisions and follow-up care in cancer diagnostics. oncgnostics is therefore active in a market, which currently shows 2-digit growth rates.
Reorganizations in the field of cervical cancer screening in several European countries will provide very attractive market opportunities for our first product GynTect®.